- Marketwired•8 hours ago
VIVUS, Inc. today announced that it will report financial results and provide a business update for the third quarter of 2016 after the NASDAQ Market closes on Wednesday, November 9, 2016. The company ...
- Zacks•15 days ago
Mylan (MYL) has agreed to pay $465 million to settle the disputes concerning the classification of EpiPen under the Medicaid drug rebate program.
- Zacks•21 days ago
VIVUS Inc. (VVUS) could be an interesting play for investors as it is seeing solid activity on the earnings estimate revision.
VIVUS Inc. (VVUS)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Day's Range||1.10 - 1.18|
|52wk Range||0.92 - 1.85|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-2.22|
|Avg Vol (3m)||360,361|
|Dividend & Yield||N/A (N/A)|